Dear Reader,
Did you catch the news that a small pharma company just leaked a letter of intent to buy 10,000 units of a still-unreleased Tesla product?
Elon Musk immediately denied the deal... calling it “fake.”
But that’s what makes this story so strange.
Why would a real company risk public humiliation by claiming it secured a product that doesn’t exist?
Unless... they believe it does.
The truth is, Musk has been dropping clues for months.Internally, he’s called this product the “biggest of all time.”
Tesla’s board offered him a $1 trillion payday to ramp up production.
He’s urging employees to “hold onto their stock”... and buying billions of it himself.
The product hasn’t launched ... yet.
But we believe it will... on November 6.
And when it does, it could send Tesla shares up as much as 3,000% , and trigger ripple effects across dozens of stocks.If the letter of intent was early... it won’t be for long.
We’ve pieced together the story, and what comes next could be the biggest market event of the year.
Get the full breakdown here before November 6.
Best,Rob Spivey
Research Director, Altimetry
The pharma company leak story is definitely unusual - companies rarely risk their reputation with false procurement announcements. That said, the article's claims about a 3,000% stock incrase seem like typical hyperbole for promotional investment content. The more interesting angle is which unreleased product this could reference. Given Tesla's current roadmap, it could be: 1) Optimus robot (mass production), 2) Robotaxi/Cybercab (regulatory approval), or 3) Energy storage expansion (new Megafactory capacity). None of these seem likely to trigger a 3,000% move though - Tesla's already a $800B+ company, which would require $24 trillion market cap. More realistic is that the pharma company was either misinformed or this was an early leak of exploratory discussions.